A detailed history of Troluce Capital Advisors LLC transactions in Cytokinetics Inc stock. As of the latest transaction made, Troluce Capital Advisors LLC holds 113,900 shares of CYTK stock, worth $5.57 Million. This represents 0.44% of its overall portfolio holdings.

Number of Shares
113,900
Previous 100,000 13.9%
Holding current value
$5.57 Million
Previous $5.42 Million 10.98%
% of portfolio
0.44%
Previous 0.66%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$51.22 - $60.16 $3.57 Million - $4.19 Million
69,602 Added 228.97%
100,000 $5.28 Million
Q2 2024

Aug 14, 2024

BUY
$47.86 - $75.05 $1.45 Million - $2.28 Million
30,398 New
30,398 $1.65 Million

Others Institutions Holding CYTK

About CYTOKINETICS INC


  • Ticker CYTK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 94,144,096
  • Market Cap $4.6B
  • Description
  • Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...
More about CYTK
Track This Portfolio

Track Troluce Capital Advisors LLC Portfolio

Follow Troluce Capital Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Troluce Capital Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Troluce Capital Advisors LLC with notifications on news.